Suppr超能文献

与临床结局相关的代谢相关脂肪性肝病新亚型:对精准医学的启示

Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.

作者信息

Hong Chang, Liang Sheng-Xing, Li Ze-Yang, Li Rui-Ning, Zhu Hong-Bo, He Mingfei, Cui Hao, He Jing-Zhe, Li Yan, Wang Jia-Ren, Zou Xue-Jing, Li Wen-Yuan, Zeng Lin, Liu Li, Xiao Lu-Shan

机构信息

Department of Health Management, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

出版信息

J Transl Med. 2025 Jul 10;23(1):769. doi: 10.1186/s12967-025-06670-5.

Abstract

BACKGROUND & AIMS: Although metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with high multimorbidity and mortality, existing classification systems and risk prediction models largely ignore the heterogeneity of MASLD. Improved subtype definition could improve prediction of outcomes and inform new precision treatment strategies.

METHODS

We analyzed individuals with MASLD from population-based electronic health record resource from UK Biobank (n = 125,197) and Health examinee dataset of Nanfang Hospital (n = 995). We identified subtypes with K-means clustering method. The Cox proportional hazard regression model analyzed the relationship between variables and MASLD-related complications.

RESULTS

After identifying five clusters across seven clinical indicators which were age, body mass index, monocyte/lymphocyte ratio, aspartate aminotransferase, waist-hip ratio, low-density lipoprotein-cholesterol, and cholesterol, we labelled MASLD subtypes: (1) Metabolic-Dyslipidemia, (2) Younger, (3) Obesity, (4) Inflammatory, and (5) Hepatotoxic. Metabolic outcomes differed across these five subtypes. Hepatotoxic MASLD showed an increased risk of severe liver diseases compared to Metabolic-Dyslipidemia MASLD [HR = 13.9, 95% CI 10.7-18.1]. The extrahepatic complications were highest in Inflammatory MASLD. These two groups were defined as the high-risk group with higher health burden than other three groups, which classified as low-risk group. Differential single-nucleotide polymorphisms were concentrated on chromosomes 1 and 19 when comparing the high- and low-risk groups, and the annotated genes enrichment pathways were primarily related to lipid metabolism and transport.

CONCLUSIONS

Patient subtypes derived by clinical indicators are a valuable addition to existing MASLD classification systems, which could provide a valuable tool to aid in selecting specific treatment approaches.

摘要

背景与目的

尽管代谢功能障碍相关脂肪性肝病(MASLD)与高合并症和高死亡率相关,但现有的分类系统和风险预测模型在很大程度上忽略了MASLD的异质性。改进亚型定义可改善对预后的预测,并为新的精准治疗策略提供依据。

方法

我们分析了来自英国生物银行基于人群的电子健康记录资源(n = 125,197)和南方医院健康体检数据集(n = 995)中的MASLD个体。我们使用K均值聚类方法识别亚型。Cox比例风险回归模型分析了变量与MASLD相关并发症之间的关系。

结果

在确定了年龄、体重指数、单核细胞/淋巴细胞比率、天冬氨酸转氨酶、腰臀比、低密度脂蛋白胆固醇和胆固醇这七个临床指标的五个聚类后,我们对MASLD亚型进行了标记:(1)代谢性血脂异常型,(2)年轻型,(3)肥胖型,(4)炎症型,(5)肝毒性型。这五种亚型的代谢结果各不相同。与代谢性血脂异常型MASLD相比,肝毒性型MASLD发生严重肝病的风险增加[风险比(HR)= 13.9,95%置信区间(CI)10.7 - 18.1]。炎症型MASLD的肝外并发症最高。这两组被定义为高风险组,其健康负担高于其他三组,后三组被归类为低风险组。比较高风险组和低风险组时,差异单核苷酸多态性集中在1号和19号染色体上,注释基因富集途径主要与脂质代谢和转运有关。

结论

通过临床指标得出的患者亚型是现有MASLD分类系统的重要补充,可为选择特定治疗方法提供有价值的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验